Companies › Genelux
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Olvimulogene nanivacirepvec Engineered oncolytic vaccinia virus | – | Phase 3 | Platinum-resistant Ovarian Cancer; Advanced Non-squamous Non-small-cell Lung Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05281471 | Olvimulogene nanivacirepvec | Phase 3 | Platinum-resistant Ovarian Cancer | Oncology | Dec 2026 |
| NCT06463665 | Olvimulogene nanivacirepvec | Phase 2 | Advanced Non-squamous Non-small-cell Lung Cancer | Oncology | Feb 2027 |
Cash and short-term investments of $19m on 2026-06-30; operating cash outflow about $25m a year; runway about 9 months at that burn, to Mar 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Imunon BriaCell Therapeutics Actinium Pharmaceuticals Oncolytics Biotech Cardiff Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.